DuPont de Nemours: An Investment Analysis Through a Long-Term Business Owner's Lens

Hunting ten-year five-baggers among great growth stocks — pressing the upside question: "Can it get much bigger?"

• QHow high is its market ceiling? Is it expanding an existing pie, or creating an entirely new market?5/10

  A

  The market ceiling is "large enough but not sexy enough": DuPont is expanding several mature existing pies, which hardly counts as "creating a brand-new market." This is the first hard flaw that keeps it from fitting Baillie Gifford's LTGG "fivefold-in-ten-years blue-sky imagination."

  First, look at which pools it is actually competing for food in today. After spinning off electronics (Qnity) and aramids (Aramids), the company has converged into two segments: 2025 continuing-operations net sales of $6.849 billion, of which Healthcare & Water Technologies (medical packaging, medical-device components, reverse-osmosis/ion-exchange/ultrafiltration water treatment) was $3.233 billion and Diversified Industrials (Tyvek home protection, STYROFOAM insulation, Corian, Vespel, Molykote, and other building and industrial materials) was $3.616 billion. These are all mature end markets whose penetration is already far from low, not new tracks grown from zero.

  What Baillie Gifford really wants to ask is "whether this pie's ceiling can support fivefold in ten years." Honestly: the half that can grow is a "structural-growth niche within a mature industry" — aging populations, more complex medical devices, water scarcity, and stricter regulation are indeed real drivers; but the increment comes from expanding the existing pie and deepening penetration, rather than creating a market that did not previously exist. Management's own 2025 Investor Day mid-term targets spell out the ceiling: only 3%–4% organic sales CAGR and 8%–10% adjusted EPS CAGR for 2025–2028. The report's judgment on this is industry attractiveness of 3/5 — "the good half is quite good, and the ordinary half is still ordinary."

  More importantly, the ceiling's "texture" is split. The H&W half is structural growth, while the DI half is mature, cyclical building/industrial materials — Q1 2026 DI organic growth was zero, held back by weak building end markets, while H&W organic growth in the same period was only 3% (reaching 6% overall only with currency). In other words, even the company's best business is currently in steady mid-single-digit growth rather than rapid expansion.

  The conclusion is this: DuPont's market ceiling is "expanding a huge but mature existing pie," not "creating a brand-new market." It is a quality materials platform assembled from structural growth + mature cyclicality; the ceiling is enough to support steady compounding, but not the kind of exponential TAM-expansion narrative Baillie Gifford looks for. Imagining it as "the next ten-bagger" gets the direction wrong.

  Jun 10, 2026
• QOver the next five years, can its revenue at least double? Is growth driven mainly by volume, price, or new businesses?3/10

  A

  Almost impossible. For DuPont's revenue to double over the next five years — from about $6.8 billion to more than $13.6 billion — would require roughly 15% annualized growth, while the company's own mid-term framework points only to mid-single digits. This is the most direct gap between it and Baillie Gifford's "revenue doubling in five years" threshold, and on this item I can only give a very low score.

  Reconcile directly with the company's official numbers. The 2025–2028 mid-term targets given at the 2025 Investor Day are 3%–4% organic sales CAGR; the full-year 2026 guidance is sales of $7.075–7.135 billion (midpoint about $7.1 billion), only about 3%–4% growth over 2025's $6.849 billion. At this pace, five years of cumulative growth could take revenue only to just over $8 billion, an order of magnitude short of "doubling." The report also directly punctures the most comparable 2023–2025 range: sales grew only from $6.614 billion to $6.849 billion, a "compound growth rate that is not impressive."

  Now break down the sources of growth — precisely what Baillie Gifford wants to probe, "volume, price, or new businesses":

  • Volume: mainly from H&W's structural demand (medical packaging, water-treatment membranes and resins); Q1 2026 medical sales delivered high-single-digit organic growth, a real volume increase; but it is largely offset by zero growth in DI building/industrial, so overall organic volume growth is only low single digits.
  • Price: a bit, but thin. The 2026 guidance includes about 1% of price contribution, explicitly meant to "fully offset" the input costs pushed up by the Middle East conflict — that is, price increases mainly hold margins in place rather than acting as a net growth engine.
  • New businesses/M&A: acquisitions such as Spectrum, Donatelle, and Sinochem are directionally concentrating toward healthcare/water treatment and can contribute some inorganic increment, but the research framework itself pegs "revenue doubling" on organic growth, and piling up revenue through constant buying is both expensive and return-dilutive.

  More important, what DuPont is truly improving is "portfolio quality and margins" rather than "growth speed." H&W's 2025 segment EBITDA margin was 30.1%, while DI was only 22.1%; the company's value-creation logic is to raise the share of the high-quality portion and lift overall margins and EPS (the 8%–10% EPS CAGR target exceeds the sales CAGR), rather than to double the top line.

  So the honest answer is: doubling revenue over the next five years is unrealistic; growth is driven mainly by volume (H&W structural demand), price only covers costs, and new businesses add but are limited. DuPont is a "steady, accelerating margin-improvement machine," not a "revenue-doubling machine" — measured by Baillie Gifford's ruler, this dimension clearly falls short.

  Jun 10, 2026
• QFive years from now, what will take over as the next growth engine? Does this "second curve" exist today?4/10

  A

  DuPont's "second curve" does exist today, and it is right inside the company — it is the steadily rising share of the high-quality Healthcare & Water Technologies business, rather than some disruptive new business yet to be born. This curve is real and visible, but it is "the better half of the main curve taking over and growing heavier," rather than the kind of independently grown, brand-new growth pole in Baillie Gifford's ideal.

  First, point to this curve. After divesting electronics and aramids, the company shifted its focus toward healthcare and water treatment: 2025 H&W net sales were $3.233 billion at a 30.1% segment EBITDA margin, clearly above Diversified Industrials' 22.1%. Baillie Gifford wants to find "who takes over in five years," and DuPont's answer is clear: let the 30%-margin H&W take an ever-larger share of total profit and push overall margins and EPS higher. Q1 2026 medical already delivered high-single-digit organic growth (driven by medical packaging and biopharma), so the direction is already being delivered.

  But to honestly cool this curve down, there are three reasons:

  First, it is an extension rather than a fresh start. Healthcare and water treatment have been DuPont's existing end markets for decades, not newly invented tracks. It is more like tuning the most efficient cylinder in the existing engine into the dominant position, rather than igniting a new engine. The "second curve" that truly excites Baillie Gifford is usually a company using existing capabilities to pry open a market that did not previously exist — and this DuPont cannot provide.

  Second, this curve itself is also only mid-single-digit growth, and it is highly dependent on bolt-on M&A to thicken it. The acquisition directions of Spectrum, Donatelle, and Sinochem are all right, but the report bluntly states that "it is still hard to prove these deals have created excess value"; growth bought this way must both pay a premium and bear integration and impairment risk.

  Third, while one leg takes over, another drags downward. DI (building technologies + industrial technologies) accounts for more than half of revenue; Q1 2026 organic growth was zero, with weak building end markets. So even if H&W takes over successfully, the whole company is only "the good half pulling and the ordinary half dragging," and the net result is steady rather than soaring.

  As for "what takes over from H&W five years later" — DuPont currently has no clear answer to this question. It has no disruptive business now being incubated that could become a new pillar in five years; the most realistic script is still H&W continuing to deepen, supplemented by bolt-on M&A around healthcare/water treatment.

  In one sentence: the second curve exists today — it is the endogenous curve of a rising H&W share, with the right direction and high profit quality — but it is an optimization and upgrade of the main curve, not an independent new growth pole; and the "third curve" has not yet emerged. For a framework like Baillie Gifford's, which bets on "regenerative, ever-flowing second curves," DuPont offers a solid but limited handoff line, not fertile soil that can grow new engines again and again.

  Jun 10, 2026
• QWhat is its core competitive advantage? Will this moat widen or narrow over the next three to five years?5/10

  A

  DuPont's core competitive advantage is "high-performance materials + certification/validation-driven switching costs + brand and applications engineering," forming, overall, a moderate-width moat (the report judges it 3/5); the trend over the next three to five years is "stable to slightly widening," but the widening mainly comes from improved portfolio structure, not from any single business suddenly digging a deeper trench. This moat is enough for it to defend the business, but it cannot support the "irreplaceable, ever-deepening" excellent barrier Baillie Gifford looks for.

  First, look at where the moat is strong and where it is weak. The hardest piece is switching costs: for medical packaging, medical-device components, water-treatment membranes/ion-exchange resins, and high-reliability industrial components, once a customer designs them into its production process, it involves validation, certification, and process adaptation, so switching suppliers is costly and risky — the report judges this item "moderate-to-high." Brand (Tyvek, Tychem, FilmTec, AmberLite, Corian, Vespel, Molykote) carries more weight in healthcare and water treatment, judged moderate. Scale rests on about 82 manufacturing sites globally and about 53% international sales, moderate. But the critical weaknesses are equally clear: no network effects (not a platform business), a moderate-to-weak cost advantage (not the lowest-cost producer), and a weak data advantage.

  Whether the moat truly "converts into profit" is the hard test of its quality — and here DuPont's checkup comes out on the cold side. Current TTM ROIC is only about 3.21% and ROE about 0.90%, far below the quality peers the report names, Veralto (ROIC about 24.8%) and Carlisle (about 20.8%). Even if these figures are understated by distortion from restructuring, spin-offs, and amortization, they show one thing: DuPont's barrier is not yet strong enough to push return on capital to a "high-quality compounder" level. A truly wide moat usually shows up as sustained high ROIC — something DuPont cannot deliver for now.

  Why equity quality also weighs on the moat's quality: as of the end of 2025, goodwill was about $7.915 billion and net other intangibles about $2.936 billion, totaling about $10.85 billion, while equity attributable to shareholders was only $13.92 billion — meaning about three-quarters of equity is not hard assets, and many "advantages" are themselves bought. A bought moat's width must be continually proven by integration quality; it is not inherently solid.

  How to judge the trend over the next three to five years:

  • Widening forces: a rising H&W share (the 30.1%-margin business growing larger), a more focused portfolio that relies more on certification and applications engineering, structurally making the overall moat steadier; the company is also institutionalizing innovation/operations/commercial excellence into a business system.
  • Narrowing risks: DI (building/industrial) already faces fuller competition and is closer to an "excellent participant in an ordinary industry"; if rivals close the performance gap, customer validation migrates successfully, or solution services are substituted, pricing power will be eroded.

  Conclusion: DuPont's moat is a moderate-width trench supported by switching costs and brand, with a steady-to-slightly-widening trend — its "width" comes from portfolio maneuvering that makes the good business heavier, rather than some barrier suddenly becoming insurmountable. By Baillie Gifford's standard, this is a qualified defensive moat, but not the offensive barrier that can drive fivefold in ten years and deepen with use; and the low ROIC is precisely the objective footnote to its being "not yet wide enough."

  Jun 10, 2026
• QIf its core business were disrupted, does it have the gene to reinvent itself? How does it treat mistakes and bad news?5/10

  A

  DuPont is one of the rare companies whose "self-reinvention gene" has been repeatedly validated — over two-plus centuries it has survived by continually switching its main business; and on treating mistakes and bad news, its disclosure counts as candid and its actions as rational, but the timing of its capital allocation shows that it "will admit mistakes, yet does not always do it beautifully." This is one of the few dimensions where DuPont can earn an above-average score against the Baillie Gifford framework.

  First, the "self-reinvention gene," which is precisely DuPont's strong suit. The implicit premise of this Baillie Gifford question is "when the core business is disrupted, can the company grow a new version of itself." DuPont's history is a chain of reinventions: from gunpowder to chemicals, to polymers such as nylon/Teflon, and now to proactively spinning off electronics (Qnity) and selling aramids (Aramids) and Delrin, converging into two segments, healthcare/water treatment + industrial/building. This latest round — post-divestiture 2025 continuing-operations net sales of $6.849 billion with clearly improved portfolio quality — is itself ready-made evidence of "proactively dismantling the old self and reassembling a new self." The report also acknowledges: today's DuPont "is no longer the large, complex chemical hodgepodge of the past." In other words, this company does not lack the courage and ability to pivot.

  Now on "how it treats mistakes and bad news," here an honest, two-sided assessment is needed:

  Candor — above average. On highly uncertain matters that are unfavorable to itself, such as spin-offs, restructuring, taxes, PFAS, and the New Jersey settlement, the company's disclosure is fairly full. The most typical is PFAS: the New Jersey natural-resource-damage settlement of $875 million over 25 years, with DuPont bearing a 35.5% share under the MOU and accruing a $177 million pre-tax charge in Q2 2025 (net-present-value basis); the report also notes the company proactively disclosed that environmental remediation costs could still run about $271 million higher than the amounts already accrued. Laying out tail bad news and accruing early is a posture of "admitting mistakes."

  Error-correction execution — mediocre, with a negative example. The most glaring is buyback timing: the report records that the company's large ASR completed in 2023 (the batch of about $3.25 billion in scale, repurchasing about 46.8 million shares at an average price of about $69) and the high-priced 2024 buyback were both bought above $70, while the $500 million ASR in Q4 2025/January 2026 averaged only about $40-something — "right direction, mediocre price" is plain to see. It will admit mistakes and dares to disclose, but on capital allocation it cannot yet be said to "learn from mistakes quickly and precisely."

  Putting both sides together: DuPont's self-reinvention gene is real and powerful — it fully deserves credit here; its attitude toward disclosing bad news is also on the candid side. But the high score for "treating mistakes" must be discounted, because on buyback timing — the clearest test of discipline — it repeatedly buys high and sells low, proving it excels at strategic pivots but not necessarily at executing every course-correction well. Baillie Gifford wants an organization that "can both reinvent itself and evolve from mistakes in a compounding way"; DuPont earns a high score on the first half and a moderate score on the second.

  Jun 10, 2026
• QDoes management (especially founders) have long-term vision and interests deeply bound to the company? Are they willing to sacrifice current profit for five to ten years out?4/10

  A

  Let me state the key upfront: DuPont has no founder and no controlling shareholder; it is a two-hundred-year-old public company run by professional managers. Its governance is standardized, its executive ownership thresholds are not low, and its long-term direction is rational, but it lacks the kind of "founder-style deep binding and ten-year discipline" Baillie Gifford values most. This is a structural gap between it and Baillie Gifford's ideal model of "founder long-term vision" — not a losing item, but genuinely unable to earn a high score.

  First, lay out the facts on governance and interest alignment. The 2026 proxy materials show that 9 of the 11 director nominees on the board are independent; the company has executive ownership requirements and retention ratios, and the report records that as of the end of 2025 the CEO's ownership requirement was 6 times salary while actual holdings reached 8.5 times; CEO Lori Koch took office in June 2024 and as of April 7, 2026 held beneficial ownership of about 500,700 shares. The company also maintains anti-hedging, anti-pledging, and clawback policies. This system is at the "modern governance benchmark" level — managers' interests are linked to the stock price, and constraint mechanisms are complete.

  But to be honest about the nature of the "binding": this is institutionalized "alignment," not founder-level "All-in." Lori Koch is a professional CEO who only took over in 2024; about 500,000 shares at the current price of about $47 is worth roughly $20-some million — big money for an individual, but a negligible share against the roughly $19 billion market cap, and not remotely in the same league as the binding in Baillie Gifford's typical heavy positions, where a founder stakes their fortune and treats the company as a life's work. There is no founder, no super-voting rights, no personalized long-termism of "raising the company like a child" — which is exactly what this Baillie Gifford question cares about most and what DuPont lacks most.

  On the half-question "whether it is willing to sacrifice current profit for five to ten years out," DuPont's answer is mixed:

  • Strategically willing: proactively spinning off electronics, selling aramids, and converging the portfolio toward high-quality healthcare/water treatment essentially means bearing short-term separation costs and accounting confusion for the sake of long-term structure — 2025 GAAP profit was only $98 million and EPS $0.21, largely the current-period price paid for the transformation. This is a real action of "sacrificing the present for the long term."
  • Discounted on capital allocation: but the same management repeatedly buys high and sells low on buyback timing — the 2023 batch of large ASRs averaged about $69, in 2024 it kept buying above $70, and only at the end of 2025 did it buy back at $40-something, plus M&A expansion in which goodwill and intangibles make up about three-quarters of equity — showing they are more like "diligent fiduciaries" than owner-type allocators who "treasure shares and spend every dollar at intrinsic value." The report scores this as management and capital allocation 3/5, "above-average honesty, moderate capital-allocation ability."

  Conclusion: DuPont's management is trustworthy, its governance transparent, and it strategically dares to sacrifice the present for the long term, but it is "excellent professional management + institutionalized alignment," not the "founder-style deep binding + extreme capital discipline" Baillie Gifford bets on. On this dimension it earns a qualified, middling score, its ceiling pressed down by both "no founder" and "mediocre buyback timing."

  Jun 10, 2026
• QIf it disappeared tomorrow, how much would customers miss it? Is its growth model sustainable and free of harm to society and regulation?5/10

  A

  Two layers here: customers' "degree of missing it" is moderate-to-high — in validation-designed links such as medical packaging, water-treatment membranes, and high-reliability industrial components, DuPont is hard to replace in the short term; but it is not the sole supplier whose disappearance would "bring the world to a halt." Its growth model is generally sustainable and does not rely on harming society; on the contrary, it rides the tailwind of stricter regulation; the only shadow is the legacy liability of PFAS. On this item DuPont is above average, but its ceiling is sealed by two points: "not indispensable" and "the PFAS tail."

  Layer one: indispensability — moderate-to-high, but not unique. The essence of this Baillie Gifford question is testing the authenticity of the barrier. DuPont's strength is switching costs: for medical packaging, medical-device components, reverse-osmosis/ion-exchange/ultrafiltration membranes, and critical industrial components, once a customer incorporates them into its production and certification process, the cost and risk of switching on short notice are extremely high, and the report judges switching costs "moderate-to-high." So if it disappeared tomorrow, the relevant customers would suffer quite a bit — line validation, compliance documents, and yields would all have to be redone from scratch. But to be honest: these markets all have strong competitors, and DuPont is "hard to replace" rather than "irreplaceable"; the report clearly says its barriers are "mostly moderate rather than absolute," and the building and industrial-technology half is closer to an "excellent participant in an ordinary industry." So customers would miss it, but not to the point of "irreplaceable, the world stops turning."

  Layer two: whether growth is sustainable and free of harm to society and regulation — basically sustainable, and directionally positive. This is a rare place where DuPont has the edge: its growth drivers today are aging populations, more complex medical devices, water scarcity, and stricter regulation — that is, stricter regulation is a tailwind rather than a headwind for it, and water treatment, medical protection, and clean drinking water are inherently pro-social businesses. As 2025 H&W net sales of $3.233 billion at a 30.1% margin grows heavier, the company's growth is increasingly tied to positive-externality scenarios such as "helping purify water and protect medical safety." It does not grow through regulatory arbitrage or by harming users — that is clean.

  The only shadow that deducts points: the legacy liability of PFAS. This is precisely the social and regulatory bill left by "the past growth model." The New Jersey natural-resource-damage settlement of $875 million over 25 years, with DuPont bearing a 35.5% share under the MOU and having already accrued a $177 million pre-tax charge for it in Q2 2025 (net-present-value basis); the report cites disclosures stating that under the MOU DuPont's PFAS cost-sharing cap is about $1.4 billion, and environmental remediation could still run about $271 million higher than the amounts already accrued (both figures per the report; refer to the latest 10-K/10-Q). This shows that its "future business" is pro-social, but "certain past chemicals" left a real environmental and regulatory burden — a tail risk hanging over the valuation rather than one that overturns its business model.

  Together: customers would miss DuPont quite a bit (moderate-to-high stickiness supported by switching costs), and its growth model is sustainable, aligned with stricter regulation, and does no harm to society — but it is "hard to replace" rather than "irreplaceable," and the PFAS historical tail discounts the claim of "fully free of reliance on harming society." Baillie Gifford wants a target whose "disappearance would break customers' hearts, and whose growth is clean enough to withstand a magnifying glass"; DuPont delivers an above-average answer of "customers would be quite inconvenienced, and the growth direction is clean but carries historical baggage."

  Jun 10, 2026
• QWhat are this business's unit economics (gross margin, incremental returns)? Does scaling up make them better or worse? Where does the money earned go?5/10

  A

  DuPont's unit economics are "two machines bolted together": the healthcare/water-treatment machine is beautiful (about 30% segment margin), and the ordinary industrial/building machine is mediocre (about 22%); scaling up by itself will not automatically make it better, and what truly determines whether unit economics are good is whether the share of the high-quality business can keep rising. Incremental returns (as measured by ROIC) are currently clearly weak, the biggest flaw of this business. The money earned flows mainly to M&A, buybacks, and legacy liabilities — the allocation direction is right, but the efficiency is mediocre.

  First, gross margin and segment margins, the base color of unit economics. 2025 cost of sales was about $4.435 billion, roughly 65% of sales, i.e., an overall gross margin of about 35%, a typical quality-materials business rather than a software one. Broken down, the gap is huge: H&W's 2025 segment EBITDA margin was 30.1%, while DI was only 22.1%. Overall Operating EBITDA margin was 23.8%, rising further to 24.6% in Q1 2026 — margins are indeed improving, but the driver is portfolio maneuvering (making the 30% machine a heavier share), not leverage from scale itself.

  Does scaling up make it better or worse? The answer is "it depends on structure, not on volume." DuPont is not an increasing-returns business where bigger means better unit economics — it has about 82 manufacturing sites globally, and more capacity/more M&A will not spread out a software-style marginal-cost advantage. Scale brings a "total-cost-of-ownership advantage + applications-engineering advantage" (the report judges the cost advantage moderate-to-weak), not winner-take-all increasing returns. So its path to improving unit economics is "shifting gears" (raising the H&W share) rather than "stepping on the gas" (simply getting bigger).

  Incremental returns — the most painful item. Whether unit economics are good ultimately comes down to how much each additional dollar of capital earns back. Current TTM ROIC is only about 3.21% and ROE about 0.90%, far below the peers the report names, Veralto (about 24.8%), Carlisle (about 20.8%), and Aptar (about 10.6%). Even if these figures are severely distorted by spin-offs, restructuring, and goodwill amortization and the true level is higher, they clearly tell you: DuPont's incremental return on capital is currently not excellent, and the report therefore directly rules "whether return on capital is excellent" a fail. A business with truly excellent unit economics should show high and stable ROIC — something DuPont cannot deliver for now.

  Where does the money earned go? Right direction, mediocre efficiency. Mainly three destinations:

  • M&A adds on: Spectrum, Donatelle, and Sinochem concentrate toward healthcare/water treatment — the direction is right, but as of the end of 2025 goodwill was about $7.915 billion, net other intangibles about $2.936 billion, totaling about $10.85 billion, showing that much of the growth was bought at high prices, with integration quality and impairment risk hanging over it for the long term.
  • Buyback returns: in May 2026 it again announced plans to launch a new $275 million ASR, but historical timing is mediocre (buying high above $70 in 2023–2024, only buying at $40-something at the end of 2025).
  • Maintenance and legacy liabilities: R&D (about $174 million in 2025), capex of $333 million, and cash payments for legacy liabilities such as PFAS will continue to eat into part of the free cash flow.

  Conclusion: DuPont's unit economics are a "quality + mediocre" hybrid, with respectable gross margins and improving margins, but the improvement relies on shifting gears rather than scale; the most critical incremental return (ROIC) is currently clearly weak, the core evidence that it does not deserve the title of "high-quality compounding machine"; the money earned is directionally correctly invested in high-quality M&A and buybacks, but both timing and integration efficiency can only be called mediocre. Baillie Gifford wants a business where "the bigger the scale the better the unit economics, with extremely high incremental returns" — DuPont delivers a middling answer of "the structure is improving, but the return has not yet proven excellent."

  Jun 10, 2026
• QFor it to rise fivefold in ten years, what conditions must hold simultaneously? Are these conditions realistic? What expectations does today's stock price imply?2/10

  A

  Straight to the conclusion: for DuPont to rise fivefold in ten years (about 17.5% annualized) requires a string of optimistic conditions that must "all hold simultaneously," several of which directly clash with the company's own mid-term framework — so this is a low-probability script. And today's price of about $47 already prices in the entire fairly optimistic set of expectations — "successful portfolio reshaping + continued margin expansion + high cash flow conversion + manageable legacy liabilities" — leaving very thin room for an upside surprise. This is one of DuPont's worst-looking dimensions under the Baillie Gifford framework.

  First, quantify "what must hold simultaneously for fivefold in ten years." Fivefold ≈ 17.5%/year total return. For a mature materials company, this must rest on the stacking of "compound profit growth × no valuation-multiple compression × dividend/buyback contribution." Break the conditions apart, and each must be delivered:

  1. Profit must far exceed the official framework. The company's 2025–2028 targets given at the Investor Day are only 8%–10% adjusted EPS CAGR. Even at the top-end 10% compounded over ten years, EPS only grows about 2.6x — far short of fivefold. To close the gap, either EPS growth must run at 15%+ for the long term (which the company itself does not guide), or it must be forced up by multiple expansion and buybacks.
  2. H&W must sustain high-quality growth and push overall margins up. H&W's 2025 margin was 30.1%, DI only 22.1%, requiring the former to take an ever-larger share without its growth slowing; but in Q1 2026 H&W organic growth was only 3% and DI organic was zero, and the building/industrial drag is a real headwind.
  3. ROIC must climb sharply from about 3% to the high single digits or above. Current TTM ROIC is only about 3.21%, and the report rules "excellent return on capital" a fail; without solving the return, the market has no reason to grant the multiple expansion fivefold requires.
  4. Legacy-liability cash flows such as PFAS/NJ must stay manageable and not be revised up. The New Jersey $875 million-over-25-years settlement, with DuPont bearing 35.5% under the MOU, and any upward revision would directly erode free cash flow and the valuation ceiling.
  5. Management must stop large buybacks at high levels or overpriced M&A, or incremental capital keeps being consumed inefficiently.

  These five must hold "simultaneously" — items 1 and 3 clearly conflict with the company's current state/official guidance — so "fivefold in ten years" has very low realism. The report's own three Owner Earnings discounting cases corroborate this: per its model, conservative intrinsic value is $22–28, neutral $30–38, and only the optimistic is $45–55, so even "fairly valued today" requires the optimistic scenario, let alone another fivefold.

  What expectations does today's price imply? This is the real bullseye of this Baillie Gifford question. Currently about $47, market cap about $19 billion, EV about $21.57 billion, EV/EBITDA about 13.9x, EV/FCF about 23.9x, forward PE about 19.4x, PB 1.37x — these multiples are not cheap for an industrial/materials company with an ROIC of only 3%. On the report's basis, the current price roughly corresponds to the range only an "optimistic DCF scenario" can cover, meaning the market has already paid for "the improvement being fully delivered." In other words, today's price implies the optimistic script of "successful portfolio reshaping, continued margin gains, high cash flow conversion, and manageable liabilities" rather than an "undervalued pessimistic expectation" — the upside has been spent in advance, and the margin of safety is negative.

  In one sentence: fivefold in ten years requires a string of interdependent optimistic conditions that conflict with the official framework to hold simultaneously, with very low realism; and today's price already prices in the optimistic script, leaving almost no room for "another fivefold beyond expectations." For Baillie Gifford's framework, which bets on "asymmetric blue-sky returns," DuPont's current price offers a symmetric-to-slightly-downward return distribution — precisely the core reason the report assigns "Watch" rather than "Buy."

  Jun 10, 2026
• QWhy hasn't the market realized all this yet? Is it not understanding, not respecting, or not seeing far enough? What would become the "narrative inflection point"?3/10

  A

  The honest answer: for DuPont, the market most likely has not "gotten it wrong" but instead sees it quite clearly — so this Baillie Gifford question does not quite hold here. This is a reasonably priced, even transformation-optimism-pre-priced, mature materials stock rather than a buried, dust-covered stock. If there is any market perception gap, it is more likely "slightly overrated" (paying a high price for the improvement story) than "not understanding, not respecting, or not seeing far enough." A narrative inflection point exists, but it is two-way — it could confirm upward or revert downward. On this dimension DuPont cannot offer the "hidden value the market has not yet realized" that Baillie Gifford wants.

  First, rule out one by one the three possibilities that "the market got it wrong":

  • Not understanding? Does not hold. DuPont is a very heavily covered large-cap, with a market cap of about $19 billion and about 405 million shares outstanding, ample sell-side coverage, and an analyst 12-month average target of about $57 (range $52–64). After divesting electronics and aramids, the portfolio is much clearer than the old DuPont, and institutions long ago studied the two segments, the margin structure, and the PFAS liability thoroughly. This is not a complex stock nobody understands.
  • Not respecting? Also basically does not hold. The fact that the valuation is not cheap shows precisely that the market has not disdained it: forward PE about 19.4x, EV/EBITDA about 13.9x, PB 1.37x, and for a company with ROIC of only about 3.21%, this is "willing to pay a premium for the improvement" pricing rather than "disdained and beaten to a floor price."
  • Not seeing far enough? Only half true. The only debatable point is that the market may not have fully granted H&W's long-term structural growth (aging, water resources, stricter regulation) a "duration" premium. But conversely, 2025 sales on the most comparable basis grew only from $6.614 billion to $6.849 billion, Q1 DI organic growth was zero, and ROIC is low — the market's withholding of a high duration premium is prudence with a factual basis, not short-sightedness.

  So the more likely truth: the market did not get it wrong; instead it priced in the optimistic expectations in advance. The report judges that the current price is already near the range only an "optimistic DCF scenario" can reasonably cover — that is, buying at about $47 today buys a future in which "the improvement has already been delivered" rather than "an undervalued today." The premise of this Baillie Gifford question (the market has not yet realized hidden value) basically does not exist for DuPont; what exists instead is the symmetric risk that "the narrative has already been fairly generously priced."

  What would the narrative inflection point be? Both directions must be seen clearly:

  • Upward-confirming inflection: several consecutive quarters of H&W organic growth holding at mid-to-high single digits, segment margins holding at or above 30%, while the DI building end market stops falling and rebounds, pushing the overall Operating EBITDA margin and ROIC up together — only then would the market be willing to re-rate it from "cyclical materials" to a "high-quality healthcare/water-treatment platform" and grant a higher duration multiple.
  • Downward-reverting inflection: if operating improvement stops accelerating, PFAS/New Jersey cash outlays are revised up, or the market reverts the multiple toward the norm for ordinary industrial materials — even if the company makes no big mistakes, shareholder returns could slide toward low single digits; the report even notes that in an extreme scenario it is not hard to imagine the stock falling back to the low-to-mid $20s to just over $30.
  • A small near-term variable is the 1-for-3 reverse stock split effective June 24, 2026 — purely a technical share-count event that does not change intrinsic value, does not constitute a real narrative inflection point, and should not mislead you via the change in nominal share price.

  In one sentence: DuPont is a mature stock that is seen very clearly and has already paid up for transformation optimism, rather than a dust-covered target the "market has not yet realized"; the real perception gap is more likely "slightly overrated" than "severely undervalued." The narrative inflection point is two-way and depends on whether H&W can keep delivering high-quality growth — precisely an operating question yet to be proven, rather than a hidden value already lying there waiting for the market to awaken. For the "asymmetric opportunity the market has not yet seen" that Baillie Gifford looks for, DuPont's current price gives a realistic answer of "already fully priced, symmetric-to-slightly-downward."

  Jun 10, 2026